Patents by Inventor Francisca Wollerton Van Horck
Francisca Wollerton Van Horck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12187798Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.Type: GrantFiled: November 23, 2021Date of Patent: January 7, 2025Assignee: INVOX PHARMA LIMITEDInventors: Mihriban Tuna, Francisca Wollerton van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
-
Publication number: 20230406935Abstract: The application relates to specific binding members which bind to programmed death-ligand 1 (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.Type: ApplicationFiled: December 8, 2022Publication date: December 21, 2023Applicant: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
-
Publication number: 20230348601Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: ApplicationFiled: February 27, 2023Publication date: November 2, 2023Inventors: Matthew John MCCOURT, Richard Charles Alfred SAINSON, Jamie Iain CAMPBELL, Stephen John ARKINSTALL, Mihriban TUNA, Ryan FIEHLER, Mustapha FAROUDI, Fadi BADR, Francisca WOLLERTON VAN HORCK, Frederick AKELE
-
Patent number: 11629189Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: GrantFiled: December 19, 2018Date of Patent: April 18, 2023Assignee: KYMAB LIMITEDInventors: Matthew John McCourt, Richard Charles Alfred Sainson, Jamie Iain Campbell, Stephen John Arkinstall, Mihriban Tuna, Ryan Fiehler, Mustapha Faroudi, Fadi Badr, Francisca Wollerton Van Horck, Frederick Akele
-
Patent number: 11548948Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.Type: GrantFiled: December 19, 2018Date of Patent: January 10, 2023Assignee: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
-
Publication number: 20220185894Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.Type: ApplicationFiled: November 23, 2021Publication date: June 16, 2022Applicant: F-star Therapeutics LimitedInventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
-
Patent number: 11214618Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.Type: GrantFiled: June 20, 2017Date of Patent: January 4, 2022Assignee: F-star Therapeutics LimitedInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
-
Patent number: 11214620Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.Type: GrantFiled: June 20, 2017Date of Patent: January 4, 2022Assignee: F-star Therapeutics LimitedInventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
-
Publication number: 20210139590Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.Type: ApplicationFiled: December 19, 2018Publication date: May 13, 2021Applicant: F-STAR BETA LIMITEDInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
-
Publication number: 20200407446Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.Type: ApplicationFiled: December 19, 2018Publication date: December 31, 2020Inventors: Matthew John MCCOURT, Richard Charles Alfred SAINSON, Jamie Iain CAMPBELL, Stephen John ARKINSTALL, Mihriban TUNA, Ryan FIEHLER, Mustapha FAROUDI, Fadi BADR, Francisca WOLLERTON VAN HORCK, Frederik AKELE
-
Publication number: 20190330344Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.Type: ApplicationFiled: June 20, 2017Publication date: October 31, 2019Applicant: F-STAR BETA LIMITEDInventors: Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
-
Publication number: 20190256602Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.Type: ApplicationFiled: June 20, 2017Publication date: August 22, 2019Applicant: F-STAR DELTA LIMITEDInventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis